HER-2 negative breast cancer accounts for around 70% of all breast cancer cases worldwide. These types of breast cancers depend on hormone receptors like estrogen and progesterone to grow. Targeted therapy drugs inhibit the action of these receptors by blocking the growth of cancer cells. The increasing adoption of targeted therapies like selective estrogen receptor modulators (SERMs), aromatase inhibitors, CDK4/6 inhibitors etc. has boosted the HER-2 negative breast cancer market growth.
The global HER-2 negative breast cancer Market is estimated to be valued at US$ 15982.51 Bn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing acceptance of targeted therapy drugs is one of the major trends propelling the Global HER-2 Negative Breast Cancer Market Size. Targeted therapies focus on specific molecular differences between cancer and normal cells that drive the growth of tumors. Drugs like tamoxifen, anastrozole, letrozole, and fulvestrant specifically target estrogen receptor-positive breast cancer cells and inhibit estrogen from attaching to these receptors and stimulating cancer growth. CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib target cell division in hormone receptor-positive tumors. Compared to chemotherapy, targeted therapy causes fewer side effects and treats cancer more effectively. Thus, the introduction of novel targeted drugs is augmenting the HER-2 negative breast cancer treatment landscape.
SWOT Analysis
Strength: HER-2 negative breast cancer accounts for around 70-75% of all breast cancer cases. Increased research and development of targeted therapies will help improve treatment options and outcomes.
Weakness: Limited treatment options as compared to HER-2 positive breast cancer. Resistance to endocrine therapies is a major challenge.
Opportunity: Growing research on immunotherapy and combination therapies provide opportunities for more effective treatment regimens. Rising healthcare expenditure in developing nations boost the market growth.
Threats: High costs associated with drug development and clinical trials. Strict regulatory approvals could delay the launch of potential drugs.
Key Takeaways
The global HER-2 negative breast cancer market is expected to witness high growth.
North America currently dominates the market owing to growing incidence of breast cancer cases and increasing healthcare spending in the region. The rising adoption of targeted therapies and growing geriatric population further boost the regional market growth.
Key players operating in the HER-2 negative breast cancer market are Robert Bosch GmbH (Germany), HELLA KGaA (Germany), Continental AG (Germany), Denso Corporation (Japan), Delphi Automotive PLC (U.K.), Autoliv Inc. (Sweden), and Valeo S.A. (France). These companies focus on collaborations, partnerships and new product launches to strengthen their market position. For instance, in 2021, Robert Bosch GmbH collaborated with Anthropic to develop safer and more reliable advanced driver-assistance systems.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it